Xeris Pharmaceuticals Inc

XERS · Moat type: REGULIERUNG

MoatScore

3/10

Fair Value

2 USD

Margin of Safety

-262.1 %

Rating

SCHWACH

GESCHÄFTSMODELL Xeris Pharmaceuticals develops and markets specialized pharmaceutical formulations based on proprietary technology platforms (in particular anhydrous glucose formulations) for endocrine and other diseases, with revenues generated primarily through prescription finished products as well as licensing and cooperation agreements.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.